Filter
624
Text search:
pharmaceutical
industry
Featured
46
150
Language
Document type
262
164
105
40
27
8
7
3
2
2
2
2
Countries
34
30
28
19
15
14
13
11
11
10
10
8
8
8
8
7
7
7
7
7
7
6
6
5
5
5
5
4
3
3
3
3
3
3
3
2
2
2
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Authors & Publishers
Publication Years
Category
231
34
27
23
14
10
4
2
Toolboxes
107
62
53
30
23
20
19
16
15
15
10
9
8
7
7
6
6
4
3
3
2
2
1
1
Social Determinants of Health Discussion Paper 1 (Debates). This paper was prepared for the launch of the Commission on Social Determinants of Health (CSDH) by its secretariat based at WHO in Geneva. It was discussed by the Commissioners and then revised considering their input.
16-17 march 2015, Geneva, Switzerland
Meeting report
Version 1.1
Department of Mental Health and Substance Abuse
A collaborative project of World Health Organization and
Lifting The Burden
Amphetamine-type stimulants, new psychoactive substances
-4-
World Drug Report 2017
Accessed: 14.03.2019
Introduction
Capter A.1
Ethics and international child and adolescent psychiatry
Global concerns: Implications for the future
Child Mental Health Atlas
This report explores the reasons why global health is critical to medicine and what this means for medical education. It argues that an understanding of global health is important for all students and practicing doctors, rather than being an ‘add-on’ or ‘option’ for specialization.
A regional consultation report and draft transition framework
The World Drug Report 2022 is aimed not only at fostering greater international cooperation to counter the impact of the world drug problem on health, governance and security, but also, with its special insights, at assisting Member States in anticipating and address-ing threats from drug markets an
...
UNAIDS 2017 / Reference
Generating evidence for policy and action on HIV and social protection
Technical Note on Antimicrobial Resistance
This document reflects UNICEF’s response to the growing global threat of AMR to child survival, growth and development. It identifies UNICEF’s AMR-specific and AMR-sensitive actions in reducing infections, promoting access to and optimal use of antimic
...
Antimicrobial resistance (AMR) is an important public health concern shared by developed and developing countries. In developing countries the burden of infectious diseases is greater and exacerbated by limited access to, and availability and affordability of, antimicrobials required to treat infect
...
Scientists have known for more than half a century that patients could develop resistance to the drugs used to treat them. Alexander Fleming, who is credited with creating the first antibiotic, penicillin, in 1928, cautioned of the impending crisis while accepting his Nobel prize in 1945: “There
...
Antimicrobial resistance (AMR) is a serious public health concern with economic, social and political implications that are global in scope, and cross all environmental and ethnic boundaries. As a global threat, AMR risks the achievements of modern medicine, and has the po
...
NAMI HelpLine
Contents
I’m having a lot of anxiety because of the coronavirus. Please help.
I’m quarantined or working from home – lonely and isolated even further – what can I do?
I don’t have health insurance or a regular doctor – how can I get care?
What if I’m quarantin
...
Global actions to reduce antimicrobial resistance (AMR) include optimising the use of antimicrobial medicines in human and animal health. In countries with weak healthcare regulation, this requires a greater understanding of the drivers of antibiotic use from the perspective of providers and consume
...
Historically, the discovery of the sulfa drugs in the 1930s and the subsequent development of penicillin during World War II ushered in a new era in the treatment of infectious diseases. Infections that were common causes of death and disease in the pre-
...
